NanoDx has signed a licensing agreement with IBM Research to use the latter’s metal-oxide semi-conductive (CMOS) compatible nanoscale sensors to boost and extend precise, rapid testing for various indications.
The companies intend to develop tests for Covid-19, traumatic brain injury (TBI), sepsis and stroke.
At present, NanoDx is seeking an emergency use authorisation from the US Food and Drug Administration for a quick Covid-19 test, which can deliver results in two minutes at point-of-care.
